Cargando…

Vaccination with virosomally formulated recombinant CyRPA elicits protective antibodies against Plasmodium falciparum parasites in preclinical in vitro and in vivo models

The Plasmodium falciparum (Pf) cysteine-rich protective antigen (PfCyRPA) has emerged as a promising blood-stage candidate antigen for inclusion into a broadly cross-reactive malaria vaccine. This highly conserved protein among various geographical strains plays a key role in the red blood cell inva...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tamborrini, Marco, Hauser, Julia, Schäfer, Anja, Amacker, Mario, Favuzza, Paola, Kyungtak, Kwak, Fleury, Sylvain, Pluschke, Gerd
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6994490/ https://www.ncbi.nlm.nih.gov/pubmed/32025340 http://dx.doi.org/10.1038/s41541-020-0158-9

Ejemplares similares

Generation of Plasmodium falciparum parasite-inhibitory antibodies by immunization with recombinantly-expressed CyRPA
por: Favuzza, Paola, et al.
Publicado: (2016)

Scalable Process for High-Yield Production of PfCyRPA Using Insect Cells for Inclusion in a Malaria Virosome-Based Vaccine Candidate
por: Fernandes, Bárbara, et al.
Publicado: (2022)

Cysteine-Rich Protective Antigen (CyRPA) as promising blood-stage candidate protein for inclusion in a malaria subunit vaccine
por: Favuzza, Paola, et al.
Publicado: (2012)

Structure of the malaria vaccine candidate antigen CyRPA and its complex with a parasite invasion inhibitory antibody
por: Favuzza, Paola, et al.
Publicado: (2017)

Structural basis for inhibition of erythrocyte invasion by antibodies to Plasmodium falciparum protein CyRPA
por: Chen, Lin, et al.
Publicado: (2017)

Strain-Dependent Inhibition of Erythrocyte Invasion by Monoclonal Antibodies Against Plasmodium falciparum CyRPA
por: Knudsen, Anne S., et al.
Publicado: (2021)

The malaria blood stage antigen PfCyRPA formulated with the TLR-4 agonist adjuvant GLA-SE elicits parasite growth inhibitory antibodies in experimental animals
por: Tamborrini, Marco, et al.
Publicado: (2023)

The RH5-CyRPA-Ripr Complex as a Malaria Vaccine Target
por: Ragotte, Robert J., et al.
Publicado: (2020)

Process development and preclinical evaluation of a major Plasmodium falciparum blood stage vaccine candidate, Cysteine-Rich Protective Antigen (CyRPA)
por: Somanathan, Anjali, et al.
Publicado: (2022)

Immunogenicity of a virosomally-formulated Plasmodium falciparum GLURP-MSP3 chimeric protein-based malaria vaccine candidate in comparison to adjuvanted formulations
por: Tamborrini, Marco, et al.
Publicado: (2011)

Neutralising antibodies block the function of Rh5/Ripr/CyRPA complex during invasion of Plasmodium falciparum into human erythrocytes
por: Healer, Julie, et al.
Publicado: (2019)

Expanding the Malaria Antibody Toolkit: Development and Characterisation of Plasmodium falciparum RH5, CyRPA, and CSP Recombinant Human Monoclonal Antibodies
por: Nacer, Adéla, et al.
Publicado: (2022)

Divergent roles for the RH5 complex components, CyRPA and RIPR in human-infective malaria parasites
por: Knuepfer, Ellen, et al.
Publicado: (2019)

RH5.1-CyRPA-Ripr antigen combination vaccine shows little improvement over RH5.1 in a preclinical setting
por: Healer, Julie, et al.
Publicado: (2022)

Bliss' and Loewe's additive and synergistic effects in Plasmodium falciparum growth inhibition by AMA1-RON2L, RH5, RIPR and CyRPA antibody combinations
por: Azasi, Yvonne, et al.
Publicado: (2020)

Design and pre-clinical profiling of a Plasmodium falciparum MSP-3 derived component for a multi-valent virosomal malaria vaccine
por: Tamborrini, Marco, et al.
Publicado: (2009)

A Virosomal Malaria Peptide Vaccine Elicits a Long-Lasting Sporozoite-Inhibitory Antibody Response in a Phase 1a Clinical Trial
por: Okitsu, Shinji L., et al.
Publicado: (2007)

Insect Cells for High-Yield Production of SARS-CoV-2 Spike Protein: Building a Virosome-Based COVID-19 Vaccine Candidate
por: Fernandes, Bárbara, et al.
Publicado: (2022)

Randomized Phase I: Safety, Immunogenicity and Mucosal Antiviral Activity in Young Healthy Women Vaccinated with HIV-1 Gp41 P1 Peptide on Virosomes
por: Leroux-Roels, Geert, et al.
Publicado: (2013)

The dual action of human antibodies specific to Plasmodium falciparum PfRH5 and PfCyRPA: Blocking invasion and inactivating extracellular merozoites
por: Weiss, Greta E., et al.
Publicado: (2023)

Virosome-Formulated Plasmodium falciparum AMA-1 & CSP Derived Peptides as Malaria Vaccine: Randomized Phase 1b Trial in Semi-Immune Adults & Children
por: Cech, Patrick Georges, et al.
Publicado: (2011)

P19-02. High protection of female macaques from repeated intravaginal challenges with SHIV-162P3 upon mucosal vaccination with Gp41 subunits-virosomes
por: Bomsel, M, et al.
Publicado: (2009)

New GMP manufacturing processes to obtain thermostable HIV-1 gp41 virosomes under solid forms for various mucosal vaccination routes
por: Amacker, Mario, et al.
Publicado: (2020)

Virosome: An engineered virus for vaccine delivery
por: Ali, Hasan, et al.
Publicado: (2023)

A Triple Co-Culture Model of the Human Respiratory Tract to Study Immune-Modulatory Effects of Liposomes and Virosomes
por: Blom, Rebecca A. M., et al.
Publicado: (2016)

A Randomized Placebo-Controlled Phase Ia Malaria Vaccine Trial of Two Virosome-Formulated Synthetic Peptides in Healthy Adult Volunteers
por: Genton, Blaise, et al.
Publicado: (2007)

Evidence of Blood Stage Efficacy with a Virosomal Malaria Vaccine in a Phase IIa Clinical Trial
por: Thompson, Fiona M., et al.
Publicado: (2008)

Using Cy5-dUTP labelling of RPA-amplicons with downstream microarray analysis for the detection of antibiotic resistance genes
por: Warmt, Christian, et al.
Publicado: (2021)

Cooperation Between Systemic and Mucosal Antibodies Induced by Virosomal Vaccines Targeting HIV-1 Env: Protection of Indian Rhesus Macaques Against Low-Dose Intravaginal SHIV Challenges
por: Lakhashe, Samir K., et al.
Publicado: (2022)

Pulmonary Delivery of Virosome-Bound Antigen Enhances Antigen-Specific CD4(+) T Cell Proliferation Compared to Liposome-Bound or Soluble Antigen
por: Blom, Rebecca A. M., et al.
Publicado: (2017)

A low dose of RBD and TLR7/8 agonist displayed on influenza virosome particles protects rhesus macaque against SARS-CoV-2 challenge
por: Koopman, Gerrit, et al.
Publicado: (2023)

Correction: Evidence of Blood Stage Efficacy with a Virosomal Malaria Vaccine in a Phase IIa Clinical Trial
por: Thompson, Fiona M., et al.
Publicado: (2011)

Development of a bead-based Luminex assay using lipopolysaccharide specific monoclonal antibodies to detect biological threats from Brucella species
por: Silbereisen, Angelika, et al.
Publicado: (2015)

Generation of monoclonal antibodies against native viral proteins using antigen-expressing mammalian cells for mouse immunization
por: Rose, Natalie, et al.
Publicado: (2016)

Genetic Diversity of Plasmodium vivax Cysteine-Rich Protective Antigen (PvCyRPA) in Field Isolates from Five Different Areas of the Brazilian Amazon
por: Bitencourt Chaves, Lana, et al.
Publicado: (2021)

Virosome Presents Multimodel Cancer Therapy without Viral Replication
por: Saga, Kotaro, et al.
Publicado: (2013)

Signal stability of Cy3 and Cy5 on antibody microarrays
por: Gu, Qiang, et al.
Publicado: (2006)

Germline landscape of RPA1, RPA2 and RPA3 variants in pediatric malignancies: identification of RPA1 as a novel cancer predisposition candidate gene
por: Sharma, Richa, et al.
Publicado: (2023)

Quick hassle-free detection of cyprinid herpesvirus 2 (CyHV-2) in goldfish using recombinase polymerase amplification-lateral flow dipstick (RPA-LFD) assay
por: Preena, Prasannan Geetha, et al.
Publicado: (2022)

Protective Efficacy of Baculovirus Dual Expression System Vaccine Expressing Plasmodium falciparum Circumsporozoite Protein
por: Iyori, Mitsuhiro, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_qd6binlrhr6hbatq3nd9tjm0c0